Effect of ipilimumab treatment on 18-month survival: Update of patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials

被引：0
|
作者：
O'Day, S.
Weber, J.
Lebbe, C.
Maio, M.
Pehamberger, H.
Harmankaya, K.
Siegel, J.
Hoos, A.
Humphrey, R.
Wolchok, J.
机构：
[1] Angeles Clin, Res Inst, Santa Monica, CA USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[3] Hop St Louis, Paris, France
[4] Univ Hosp Siena, Ist Toscano Tumori, Siena, Italy
[5] Univ Vienna, Vienna, Austria
[6] Med Univ Vienna, Univ Dermatol, Vienna, Austria
[7] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[8] Bristol Myers Squibb Co, Princeton, NJ USA
[9] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9033
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Association between immune-related adverse events (irAEs) and disease control or overall survival in patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials
    Lutzky, J.
    Wolchok, J.
    Hamid, O.
    Lebbe, C.
    Pehamberger, H.
    Linette, G.
    de Pril, V.
    Ibrahim, R.
    Hoos, A.
    O'Day, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] Ipilimumab (Ipi) retreatment at 10 mg/kg in patients with metastatic melanoma previously treated in phase II trials
    Neyns, Bart
    Weber, Jeffrey S.
    Lebbe, Celeste
    Maio, Michele
    Harmankaya, Kaan
    Hamid, Omid
    O'Day, Steven
    Chin, Kevin M.
    McDowell, Diane Opatt
    Cykowski, Lori
    McHenry, Brent
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Long-term survival in advanced melanoma patients treated with ipilimumab at 10 mg/kg: ongoing analyses from completed Phase II trials
    Maio, M.
    Lebbe, C.
    Sileni, V. Chiarion
    Siegel, J.
    Hoos, A.
    Humphrey, R.
    O'Day, S.
    Wolchok, J.
    Weber, J.
    Harmankaya, K.
    EJC SUPPLEMENTS, 2009, 7 (02): : 578 - 578
  • [4] Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials
    Reinhard Dummer
    Dirk Schadendorf
    Paolo A Ascierto
    James Larkin
    Celeste Lebbé
    Axel Hauschild
    Journal of Translational Medicine, 12 (Suppl 1)
  • [5] Efficacy of ipilimumab 10 mg/kg in advanced melanoma patients (pts) with good and poor prognostic factors
    Wolchok, J. D.
    de Pril, V.
    Linette, G.
    Waterfield, W.
    Gajewski, T.
    Chiarion-Sileni, V.
    Ibrahim, R.
    Chin, K.
    Hoos, A.
    Hamid, O.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] FIVE-YEAR SURVIVAL RATES FOR PATIENTS (PTS) WITH METASTATIC MELANOMA (MM) TREATED WITH IPILIMUMAB (IPI) IN PHASE II TRIALS
    Lebbe, Celeste
    Weber, Jeff
    Maio, Michele
    Neyns, Bart
    Harmankaya, Kaan
    Chin, Kevin
    McDowell, Diane
    Cykowski, Lori
    McHenry, Brent
    Wolchok, Jedd
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 : 309 - 309
  • [7] FIVE-YEAR SURVIVAL RATES FOR PATIENTS (PTS) WITH METASTATIC MELANOMA (MM) TREATED WITH IPILIMUMAB (IPI) IN PHASE II TRIALS
    Lebbe, C.
    Weber, J. S.
    Maio, M.
    Neyns, B.
    Harmankaya, K.
    Chin, K.
    McDowell, D. Opatt
    Cykowski, L.
    McHenry, M. B.
    Wolchok, J. D.
    ANNALS OF ONCOLOGY, 2012, 23 : 363 - 364
  • [8] Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
    Ascierto, Paolo Antonio
    Del Vecchio, Michele
    Mackiewicz, Andrzej
    Robert, Caroline
    Chiarion-Sileni, Vanna
    Arance, Ana
    Lebbe, Celeste
    Svane, Inge Marie
    McNeil, Catriona
    Rutkowski, Piotr
    Loquai, Carmen
    Mortier, Laurent
    Hamid, Omid
    Bastholt, Lars
    Dreno, Brigitte
    Schadendorf, Dirk
    Garbe, Claus
    Nyakas, Marta
    Grob, Jean-Jacques
    Thomas, Luc
    Liszkay, Gabriella
    Smylie, Michael
    Hoeller, Christoph
    Ferraresi, Virginia
    Grange, Florent
    Gutzmer, Ralf
    Pikiel, Joanna
    Hosein, Fareeda
    Simsek, Burcin
    Maio, Michele
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [9] Overall Survival (OS) and New Patterns of Response in Patients (Pts) With Advanced Melanoma Treated With Ipilimumab
    O'Day, Steven
    Ibrahim, Ramy
    De Pril, Veerle
    Maio, Michele
    Sileni, Vanna Chiarion
    Gajewski, Thomas F.
    Pehamberger, Hubert
    Bondarenko, Igor N.
    Queirolo, Paola
    Lundgren, Lotta
    Mikhailov, Sergey
    Roman, Laslo
    Verschraegen, Claire
    Hoos, Axel
    Humphrey, Rachel
    Wolchok, Jedd
    JOURNAL OF IMMUNOTHERAPY, 2008, 31 (09) : 937 - 938
  • [10] Long-term survival of patients (pts) with advanced melanoma treated with ipilimumab with or without dacarbazine
    Hersh, E.
    Weber, J.
    Powderly, J.
    Pavlik, A.
    Nichol, G.
    Yellin, M.
    Cranmer, L.
    Urba, W.
    O'Day, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345